I meant to add in my previous post that Eyelea’s regulatory exclusivity ends on 17th May 2024 and the key patent expires at end of June. Let’s see how keen Regeneron is to maintain its profit margin. A potential combination therapy could well be in their interests. It can be all about timing and Opthea may just be in the right place at the right time.
I meant to add in my previous post that Eyelea’s regulatory...
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
52.0¢ |
Change
0.030(6.12%) |
Mkt cap ! $344.6M | |||
| Open | High | Low | Value | Volume |
| 48.5¢ | 52.0¢ | 48.3¢ | $273.6K | 546.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 47051 | 50.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 52.0¢ | 16084 | 2 |
View Market Depth
| Last trade - 16.10pm 05/06/2024 (20 minute delay) ? |
|
|||||
|
Last
51.8¢ |
Change
0.030 ( 4.86 %) |
||||
| Open | High | Low | Volume | ||
| 48.5¢ | 52.0¢ | 48.5¢ | 102223 | ||
| Last updated 15.59pm 05/06/2024 ? | |||||
| OPT (ASX) Chart |